IA
IART.US Integra LifeSciences Holdings
- Market cap
- USD 1.12B
- P/E
- 84.7x
- P/B
- 0.45x
- ROE
- 1.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is IART.US undervalued?
Graham numberIART.US trades 30.7% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Integra LifeSciences Holdings fundamental analysis
No fundamental analysis for Integra LifeSciences Holdings yet.
Integra LifeSciences Holdings stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Integra LifeSciences Holdings
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitori…
Full company profileIntegra LifeSciences Holdings financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Integra LifeSciences Holdings annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 992M | 1.19B | 1.47B | 1.52B | 1.37B | 1.54B | 1.56B | 1.54B | 1.61B | 1.64B | 1.63B |
| Gross Profit | 643M | 753M | 901M | 953M | 851M | 945M | 970M | 885M | 882M | 845M | 872M |
| Operating Income | 115M | 44.8M | 111M | 93.8M | 151M | 197M | 239M | 112M | 28.4M | 68.3M | 104M |
| EBITDA | 232M | 135M | 236M | 224M | 265M | 362M | 382M | 256M | 193M | -325M | 223M |
| Net Income | 74.6M | 64.7M | 60.8M | 50.2M | 134M | 169M | 181M | 67.7M | -6.94M | -516M | 19.6M |
| EPS | 0.94 | 0.82 | 0.72 | 0.58 | 1.57 | 1.98 | 2.16 | 0.84 | -0.09 | -6.73 | 0.25 |
| Balance Sheet | |||||||||||
| Total Assets | 1.81B | 3.21B | 3.11B | 3.30B | 3.62B | 3.78B | 3.89B | 3.78B | 4.04B | 3.60B | 3.51B |
| Total Liabilities | 968M | 2.25B | 1.73B | 1.89B | 2.10B | 2.10B | 2.09B | 2.19B | 2.49B | 2.56B | 2.44B |
| Shareholders' Equity | 840M | 962M | 1.38B | 1.42B | 1.51B | 1.68B | 1.80B | 1.59B | 1.55B | 1.04B | 1.07B |
| Cash & Short-term Investments | 102M | 175M | 139M | 199M | 470M | 513M | 457M | 309M | 274M | 264M | 312M |
| Total Debt | 665M | 1.84B | 1.35B | 1.46B | 1.66B | 1.67B | 1.63B | 1.68B | 1.98B | 2.03B | 2.00B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 116M | 115M | 200M | 231M | 204M | 312M | 264M | 140M | 129M | 50.4M | 171M |
| Capital Expenditure | 47.3M | 43.5M | 77.7M | 135M | 63.9M | 48.1M | 47.1M | 66.9M | 104M | 95.6M | 49.9M |
| Free Cash Flow | 69.1M | 71.0M | 122M | 96.9M | 140M | 264M | 217M | 73.1M | 25.0M | -45.3M | 122M |
| Ratios | |||||||||||
| ROE | 8.9% | 6.7% | 4.4% | 3.5% | 8.8% | 10.0% | 10.0% | 4.3% | -0.4% | -49.5% | 1.8% |
| ROA | 4.1% | 2.0% | 2.0% | 1.5% | 3.7% | 4.5% | 4.6% | 1.8% | -0.2% | -14.3% | 0.6% |
| Net Profit Margin | 7.5% | 5.4% | 4.1% | 3.3% | 9.8% | 11.0% | 11.6% | 4.4% | -0.4% | -31.6% | 1.2% |
| Debt to Equity | 0.79x | 1.91x | 0.98x | 1.03x | 1.09x | 0.99x | 0.90x | 1.06x | 1.28x | 1.95x | 1.88x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Integra LifeSciences Holdings dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 93.2M | 1.16 | 137.6% |
| 2022 | USD 5.47M | 0.07 | 3.0% |
| 2021 | USD 2.02M | 0.02 | 1.2% |
| 2020 | USD 44.6M | 0.52 | 33.3% |
| 2019 | USD 434K | 0.01 | 0.9% |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Jan 4, 2017.
Who owns Integra LifeSciences Holdings
- Insiders 14.58%
- Institutions 85.42%
- Public & others 0.00%
- Shares outstanding 77.8M
- Free float 58.6M
Top funds holding IART.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 3.99M | 5.12% | +0.06% | Oct 2026 |
| Invesco Small Cap Value A | 3.79M | 4.87% | +5.11% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 2.11M | 2.71% | 0.00% | Sep 2026 |
| Undiscovered Managers Behavioral Val L | 1.79M | 2.30% | -33.95% | Sep 2026 |
| iShares Russell 2000 ETF | 1.72M | 2.21% | 0.00% | Oct 2026 |
| Vanguard Small Cap Index | 1.49M | 1.91% | -2.03% | Sep 2026 |
| DFA U.S. Small Cap Value I | 1.04M | 1.33% | +80.61% | Sep 2026 |
| Vanguard MStar Small Cap Value Index | 969K | 1.25% | +0.25% | Sep 2026 |
| Glenmede Small Cap Equity Adv | 772K | 0.99% | -10.19% | Sep 2026 |
| Fidelity Small Cap Index | 750K | 0.96% | +0.29% | Aug 2026 |
| PIMCO RAE US S Instl | 651K | 0.84% | +5.12% | Jun 2026 |
| iShares Russell 2000 Value ETF | 646K | 0.83% | 0.00% | Oct 2026 |
| State Street SPDR Port S&P 600 Sm CpETF | 602K | 0.77% | -0.05% | Oct 2026 |
| Neuberger Intrinsic Value I | 560K | 0.72% | 0.00% | Sep 2026 |
| iShares S&P Small-Cap 600 Value ETF | 548K | 0.70% | 0.00% | Oct 2026 |
| Schwab Fundamental U.S. Small CompanyETF | 485K | 0.62% | 0.00% | Oct 2026 |
| Vanguard Explorer Value Inv | 457K | 0.59% | +2.58% | Sep 2026 |
| Dimensional US Small Cap Value ETF | 419K | 0.54% | +0.06% | Sep 2026 |
| Vanguard Russell 2000 ETF | 398K | 0.51% | +1.22% | Sep 2026 |
| Invenomic Institutional | 395K | 0.51% | -46.14% | Jul 2026 |
Top institutions holding IART.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 10.7M | 13.74% | +3.54% | Jun 2026 |
| Rubric Capital Management LP | 7.75M | 9.97% | 0.00% | Jun 2026 |
| Amvescap Plc. | 3.75M | 4.82% | +7.57% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 3.74M | 4.81% | +1.53% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 3.59M | 4.62% | +0.25% | Jun 2026 |
| Paradigm Capital Management, Inc. | 3.44M | 4.42% | -14.29% | Jun 2026 |
| Fuller & Thaler Asset Management Inc | 3.44M | 4.42% | -2.65% | Jun 2026 |
| State Street Corp | 2.95M | 3.79% | +2.09% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.95M | 3.79% | +1.91% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 2.77M | 3.56% | +24.76% | Sep 2026 |
| Neuberger Berman Group LLC | 2.36M | 3.04% | +11.80% | Jun 2026 |
| Geode Capital Management, LLC | 1.79M | 2.30% | +8.13% | Jun 2026 |
| The Goldman Sachs Group Inc | 1.47M | 1.89% | -21.47% | Jun 2026 |
| Wellington Management Company LLP | 1.46M | 1.88% | +12.37% | Jun 2026 |
| Millennium Management LLC | 1.44M | 1.85% | +131.15% | Jun 2026 |
| Charles Schwab Investment Management Inc | 1.40M | 1.80% | -13.07% | Jun 2026 |
| Bank of America Corp | 1.33M | 1.71% | -6.03% | Jun 2026 |
| Systematic Financial Management LP | 1.02M | 1.32% | -3.40% | Jun 2026 |
| Allianz Asset Management AG | 1.01M | 1.29% | +12.99% | Jun 2026 |
| Glenmede Trust Co NA | 948K | 1.22% | -3.71% | Jun 2026 |
Integra LifeSciences Holdings company profile
- Company name
- Integra LifeSciences Holdings
- Ticker
- IART.US
- Exchange
- USA Stocks
- Listed since
- Aug 16, 1995
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 4,427
- Fiscal year end
- December
- Address
- 1100 Campus Road, Princeton, NJ, United States, 08540
- Phone
- 609 275 0500
- Website
- integralife.com
About Integra LifeSciences Holdings
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. It also offers after-market services; surgical headlamps and instrumentation; instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. In addition, the company provides treatment of acute wounds, such as burns; chronic wounds, including diabetic foot ulcers; and surgical tissue repair applications, including hernia reinforcement, tendon protection, and peripheral nerve repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, and nerve and tendon repair products. Additionally, the company is involved in the ear, nose, and throat business that includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, and surgical navigation systems. It offers its products directly through various salesforces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, the Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was formerly known as Integra LifeSciences Corp. and changed its name to Integra LifeSciences Holdings Corporation in June 1995. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
Integra LifeSciences Holdings management
10- Dr. Stuart M. Essig Ph.D.CEO, President & Chairman · born 1962
- Ms. Lea Daniels KnightExecutive VP & CFO · born 1972
- Mr. Robert T. Davis Jr.Executive Vice President of Tissue Reconstruction and Distributed Technologies · born 1959
- Mr. Michael J. McBreenExecutive VP & Chief Commercial Officer · born 1966
- Mr. Harvinder Pal SinghExecutive VP & President of International Business · born 1966
- Mr. Jeffrey A. MosebrookSenior VP of Finance & Principal Accounting Officer · born 1976
- Mr. Teshtar ElaviaCorporate VP & Chief Technology Officer
- Christopher WardSenior Director of Investor Relations
- Mr. Michael D. HutchinsonExecutive VP, Chief Legal Officer & Secretary · born 1971
- Laurene IsipVice President of Global Corporate Communications & Public Relations